Skip to main content
TipRanks
Go Ultimate75% OFF

Scandinavian Real Heart AB (7820) AI Stock Analysis

1 Followers
DE:7820

Scandinavian Real Heart AB

(Frankfurt:7820)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Specialized Artificial Heart PlatformA focused artificial-heart platform addresses a severe clinical need where transplantation and other mechanical support options may not be suitable. If validation and regulatory work progress, this specialized product could support a differentiated position in cardiovascular devices over the medium term.
Negative Factors
Pre-Revenue Commercial PositionThe absence of a meaningful revenue base shows that the Realheart TAH has not yet established recurring commercial demand or demonstrated market adoption. Until approvals and sales scale are achieved, business performance remains dependent on development progress rather than operating revenue.

Scandinavian Real Heart AB (7820) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:7820-44.23%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 12.06M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-2.2
Beta (1Y)
-0.04
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Scandinavian Real Heart AB Business Overview & Revenue Model

Company Description

Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to...

Scandinavian Real Heart AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7820 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.53B26.699.13%1.71%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.925.89%―17.83%330.94%
SE:BRAINSE:BRAIN54NeutralSEK 473.85M-12.99-19.29%―0.04%34.45%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 464.07M-24.58-15.00%―11.18%60.51%
SE:ACARIXSE:ACARIX45NeutralSEK 201.21M-5.10-96.06%―40.61%32.63%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:7820SE:GETI.BSE:XVIVOSE:ACARIXSE:BRAINSE:MNTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7820 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7820Scandinavian Real Heart AB1.30-1.03-44.23%
SE:GETI.BGetinge AB (UK)278.0076.3537.86%
SE:XVIVOXvivo Perfusion AB197.2031.6019.08%
SE:ACARIXAcarix AB0.16-0.11-41.76%
SE:BRAINBrainCool AB1.190.61106.26%
SE:MNTCMentice AB16.953.1522.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.